Infectious Diseases, Microbiology

Our research is focusing on developing novel therapeutics and antibiotics-alternative approaches, including probiotics, anti-virulence and quorum sensing inhibitors, small molecules, and peptides to mitigate infectious pathogens and antimicrobial resistance (AMR) in animals and in humans. Our research is also focused on understanding the host-pathogen interactions and elucidating the impact of novel therapeutics on the host gut microbiome using molecular and omics-based approaches. We also study epidemiology, antibiotic resistance profiles, genetic diversity, and risk assessment of AMR of foodborne pathogens (Campylobacter, Salmonella, E. coli O157, and Listeria monocytogens) using molecular tools and genomics for the detection of AMR determinants to combat the increasing threat of AMR.

Research Areas of Interest

• Food Safety and Public Health
• Antimicrobial resistance
• Drug discovery
• Nanoparticles
• Gut Microbiome
• One Health
• Molecular epidemiology
• Diagnosis of infectious diseases